Morgan Stanley Boosts Becton, Dickinson and Company (BDX) Price Target to $245.00

Becton, Dickinson and Company (NYSE:BDX) had its price objective hoisted by stock analysts at Morgan Stanley from $205.00 to $245.00 in a note issued to investors on Friday, November 3rd. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Morgan Stanley’s price target would suggest a potential upside of 9.26% from the company’s previous close.

BDX has been the subject of several other research reports. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Royal Bank Of Canada restated a “hold” rating and issued a $210.00 target price on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price for the company in a research note on Tuesday, October 31st. Cowen and Company restated an “outperform” rating and issued a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $210.00 price target (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $217.08.

Shares of Becton, Dickinson and (NYSE BDX) traded down $2.60 on Friday, hitting $224.23. The company had a trading volume of 1,161,293 shares, compared to its average volume of 1,322,929. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. Becton, Dickinson and has a 12 month low of $161.29 and a 12 month high of $227.50. The company has a market cap of $51,030.00, a PE ratio of 23.34, a P/E/G ratio of 1.73 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same period last year, the business earned $2.12 EPS. The business’s revenue was down 2.0% on a year-over-year basis. analysts anticipate that Becton, Dickinson and will post 10.63 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/becton-dickinson-and-company-bdx-pt-raised-to-245-00/1755423.html.

In related news, insider Stephen Sichak sold 11,787 shares of the stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the sale, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the company. Almanack Investment Partners LLC. bought a new stake in shares of Becton, Dickinson and in the 1st quarter valued at approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares during the last quarter. Parkside Financial Bank & Trust lifted its stake in shares of Becton, Dickinson and by 8.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 51 shares during the last quarter. Harfst & Associates Inc. lifted its stake in shares of Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares during the last quarter. Finally, Financial Architects Inc lifted its stake in shares of Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares during the last quarter. 87.91% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.